{"id":1905,"date":"2018-09-12T09:00:30","date_gmt":"2018-09-12T09:00:30","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-gains-market-acceptance-in-austria-new-customers-orders-cadscorsystem-for-ruling-out-coronary-artery-disease-cad\/"},"modified":"2024-08-06T12:25:36","modified_gmt":"2024-08-06T12:25:36","slug":"acarix-gains-market-acceptance-in-austria-new-customers-orders-cadscorsystem-for-ruling-out-coronary-artery-disease-cad","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-gains-market-acceptance-in-austria-new-customers-orders-cadscorsystem-for-ruling-out-coronary-artery-disease-cad\/","title":{"rendered":"Acarix gains market acceptance in Austria; new customers orders CADScor\u00aeSystem for ruling out Coronary Artery Disease (CAD)."},"content":{"rendered":"
<\/strong><\/div>\n

Press release
Malm\u00f6, September 12, 2018<\/p>\n

Acarix gains market acceptance in Austria;
new customers orders CADScor\u00aeSystem for ruling out Coronary Artery Disease (CAD).<\/strong><\/p>\n

Acarix AB (publ) ("Acarix") reports first sales in Austria for its handheld CADScor\u00aeSystem for early rule-out of CAD.\u00a0 The Austrian sales mirror growing success in neighboring Germany where the market is very similar with high numbers of both potential private and public customers.<\/strong><\/p>\n

"By using the unique technology provided by Acarix and the CADScor\u00ae System\u00a0I can limit the number of patients that will be referred to coronary angiography.\u00a0This will help shorten waiting lists and add value for both patients and the\u00a0healthcare system. We have lowered the\u00a0numbers of patients that actually have to be exposed to further examinations and thereby saving expenses to the hospital\u00a0" says Dr Werner Kommer, Facharzt f\u00fcr Innere Medizin und Kardiologie in Wolkersdorf,\u00a0Austria.<\/em><\/p>\n

"Our entry to the Austrian market marks a major step forward"<\/em>says Per Persson, Chief Commercial Officer at Acarix. "Our three new accounts confirm the benefits of the technology and its suitability for both private and public healthcare settings. We look forward to building on this throughout the Austrian market."
<\/em><\/em><\/p>\n

The CADScor\u00aeSystem combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 8 minutes. This provides physicians with a rapid front line tool for early assessment before moving on to more expensive invasive methods.<\/p>\n<\/p>\n

Contacts:<\/strong><\/p>\n

Christian Lindholm, interim CEO, E-mail: secli@acarix.com, Phone: +46 705 118\u00a0333<\/p>\n

Notes to editors:<\/strong>
Acarix, CADScor\u00aeSystem and cardiac sound measurement
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix's CADScor\u00aeSystem uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor\u00aeSystem thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures.<\/p>\n

See more at www.acarix.com<\/a>. Press photos: http:\/\/www.acarix.com\/about-us\/press-downloads\/press-photos\/<\/a>. Press release Austria-ENG.<\/a><\/p>\n

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire<\/em><\/p>\n

<\/div>\n